Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 19/20 | 0.51 |
| ▸ | SRC | P12931 | 7/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 8/20 | 0.43 |
| ▸ | FLT1 | P17948 | 4/20 | 0.43 |
| ▸ | FLT4 | P35916 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750779 | 0.88 | FGFR1 (0.43) | FGFR1SRCSLC22A12KDR | |
| SCHEMBL5749722 | 0.85 | FGFR1 (0.51) | FGFR1SRCSLC22A12FGFR2FGFR4 | |
| SCHEMBL5774197 | 0.84 | FGFR1 (0.59) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL5748453 | 0.83 | FGFR1 (0.56) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL5750480 | 0.83 | KMT2A (0.47) | FGFR1PDGFRBEGFRKDRFLT1 | |
| SCHEMBL5750526 | 0.81 | FGFR1 (0.51) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL5750761 | 0.81 | MEN1 (0.55) | KDR | |
| SCHEMBL5748752 | 0.80 | ALDH1A1 (0.51) | FGFR1 | |
| SCHEMBL5748810 | 0.80 | NPC1 (0.50) | — | |
| SCHEMBL5748668 | 0.80 | FGFR1 (0.62) | FGFR1SRCPDGFRBPDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372648-B1 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| US-7005434-B2 | Compounds and uses thereof | SB CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040048888-A1 | Novel compounds and uses thereof | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048888-A1 | Novel compounds and uses thereof | TEK, TIE1, KDR | FGFR1 24/4885SRC 1144/4885PDGFRB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.